Furthermore, while this study establishes EMP1 as a novel marker and potential therapeutic target for HSC activation in MASLD-IRI, a direct comparative analysis of its sensitivity against classical HSC activation markers (α-SMA, COL1A2) is still lacking. This evidence concerns the gene COL1A2 and metabolic dysfunction-associated steatotic liver disease.